Medpace (NASDAQ:MEDP) Releases FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 17.250-17.950 for the period, compared to the consensus estimate of 17.070. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.8 billion.

Medpace Trading Down 0.7%

NASDAQ:MEDP opened at $528.12 on Thursday. The firm has a market cap of $15.08 billion, a PE ratio of 33.19, a price-to-earnings-growth ratio of 2.66 and a beta of 1.15. The stock has a fifty day moving average price of $484.63 and a 200 day moving average price of $493.49. Medpace has a 12-month low of $373.00 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.53 million. During the same quarter in the prior year, the business earned $3.10 EPS. Medpace’s revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities analysts forecast that Medpace will post 17.04 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on MEDP shares. Barclays lowered their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and raised their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Robert W. Baird reissued a “neutral” rating and issued a $547.00 price target (up from $477.00) on shares of Medpace in a report on Wednesday, July 8th. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Two investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $473.09.

Insider Activity

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 20.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Medpace

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Geneos Wealth Management Inc. raised its stake in Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Quarry LP bought a new stake in Medpace in the third quarter valued at $35,000. Greenline Wealth Management LLC acquired a new position in shares of Medpace during the fourth quarter valued at $55,000. Group One Trading LLC grew its position in shares of Medpace by 120.0% during the fourth quarter. Group One Trading LLC now owns 100 shares of the company’s stock worth $56,000 after acquiring an additional 600 shares during the last quarter. Finally, Johnson Financial Group Inc. grew its position in Medpace by 115.7% in the 3rd quarter. Johnson Financial Group Inc. now owns 110 shares of the company’s stock worth $57,000 after purchasing an additional 59 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.